Achaogen (AKAO) Reports Q4 Loss Per Share of 98c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Achaogen (AKAO) Reports Q4 Loss Per Share of 98c

Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

February 27, 2018 4:01 PM EST

-- Plazomicin New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA);June 25, 2018 set as PDUFA action date --

-- Orally-administered antibacterial candidate C-Scape achieved positive top-line results in Phase 1 --

-- Conference call today at 4:30 p.m. Eastern Time --

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today reported financial results for the fourth quarter and year ended... More